American Society of Clinical Oncology

SHERPA: White

People

  1. Miller
    Miller
  2. Kris
    Kris
  3. Riely
    Riely
  4. Ladanyi
    Ladanyi
  5. Heelan
    Heelan
  6. Arcila
    Arcila
  7. Ginsberg
    Ginsberg
  8. Rusch
    Rusch
  9. Drilon
    Drilon
  10. Dunne
    Dunne

Groups

  1. Department of Medicine (41)
  2. Solid Tumor Oncology Division (41)
  3. Thoracic Oncology (39)
  4. GSK Faculty (16)
  5. Human Oncology and Pathogenesis Program (16)
  6. Tow Center for Developmental Oncology (TCDO) (16)
  7. Gastrointestinal Oncology Service (6)
  8. Nursing (6)
  9. Biostatistics Service (5)
  10. Body Imaging Service (5)
Search Within
  1. "Vincent Miller"
  2. "Meeting abstract"
Formats
  1. Meeting Abstract (55)
Groups
  1. Department of Medicine (41)
  2. Solid Tumor Oncology Division (41)
  3. Thoracic Oncology (39)
  4. GSK Faculty (16)
  5. Human Oncology and Pathogenesis Program (16)
  6. Tow Center for Developmental Oncology (TCDO) (16)

More Groups

People
  1. Vincent Miller (55)
  2. Mark Kris (37)
  3. Gregory Riely (24)
  4. William Pao (17)
  5. Marc Ladanyi (16)
  6. Naiyer Rizvi (13)

More People

Years
  1. 2017 (2)
  2. 2016 (1)
  3. 2015 (1)
  4. 2014 (2)
  5. 2012 (2)
  6. 2011 (3)

More Years

Publications
  1. Journal of Clinical Oncology (55)

Results (55)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Reproducibility of computed tomography (CT) measurements of lung cancer
    Meeting Abstract

    James, L. P.; Zhao, B.; Moskowitz, C. S.; Riely, G. J.; Miller, V. A.; Guo, P.; Ginsberg, M. S.; Kris, M. G.; Schwartz, L. H.
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save
  • Safety of bevacizumab (Bv) therapy in combination with chemotherapy in subjects with non-small cell lung cancer (NSCLC) treated on ATLAS
    Meeting Abstract

    Polikoff, J.; Hainsworth, J. D.; Fehrenbacher, L.; Royer-Joo, S.; Mu, Y.; Strickland, D. K.; Miller, V. A.
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save
  • Activity of XL647 in clinically selected NSCLC patients (pts) enriched for the presence of EGFR mutations: Results from Phase 2
    Meeting Abstract

    Rizvi, N. A.; Kris, M. G.; Miller, V. A.; Krug, L. M.; Bekele, S.; Dowlati, A.; Rowland, K. M.; Salgia, R.; Aggarwal, N.; Gadgeel, S. M.
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save
  • A randomized phase II trial comparing pulsed erlotinib before or after carboplatin and paclitaxel in patients with stage IIIB or IV non-small cell lung cancer
    Meeting Abstract

    Riely, G. J.; Rudin, C. M.; Kris, M. G.; Senturk, E.; Azzoli, C. G.; Brahmer, J.; Fogle, M.; Ginsberg, M.; Miller, V. A.; Rizvi, N. A.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • Smoking history and frequency of somatic KRAS mutations in adenocarcinoma of the lung
    Meeting Abstract

    Miller, V. A.; Riely, G. J.; Kris, M. G.; Rosenbaum, D.; Marks, J.; Li, A.; Chitale, D.; Nafa, K.; Pao, W.; Ladanyi, M.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • Phase II study of the efficacy and safety of intravenous (IV) AVE0005 (VEGF Trap) given every 2 weeks in patients (Pts) with platinum- and erlotinib- resistant adenocarcinoma of the lung (NSCLA)
    Meeting Abstract

    Massarelli, E.; Miller, V. A.; Leighl, N. B.; Rosen, P. J.; Albain, K. S.; Hart, L. L.; Melnyk, O.; Sternas, L.; Ackerman, J.; Herbst, R. S.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • Phase I study of the antifolate pralatrexate given with vitamin B(12) and folic acid supplementation in patients (pts) with advanced non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Azzoli, C. G.; Krug, L.; Miller, V.; Bekele, S.; Tyson, L.; Dunne, M.; Huntington, M.; Saunders, M.; Kris, M. G.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • Phase I/II study of ABI-007 as first line chemotherapy in advanced non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Rizvi, N. A.; Azzoli, C.; Miller, V.; Ng, K.; Fiore, J.; Chia, G.; Brower, M.; Heelan, R.; Hawkins, M.; Kris, M.
    Journal of Clinical Oncology (2006)

    Fulltext@MSK | Save
  • Prospective FDG-PET and CT assessment of discontinuation of erlotinib (E) or gefitinib (G) in patients with EGFR TKI sensitive non-small cell lung cancer (NSCLC) who subsequently progress radiographically on E or G ("acquired resistance") followed by re-initiation of E or G and the subsequent addition of everolimus (RAD001)
    Meeting Abstract

    Riely, G. J.; Kris, M. G.; Schwartz, L. H.; Akhurst, T.; Zhao, B.; Milton, D. T.; Moore, E.; Tyson, L.; Pao, W.; Miller, V. A.
    Journal of Clinical Oncology (2006)

    Fulltext@MSK | Save
  • Molecular analysis of NSCLC patients with acquired resistance to gefitinib or erlotinib
    Meeting Abstract

    Pao, W.; Balak, M. N.; Riely, G. J.; Li, A. R.; Zakowski, M. F.; Ladanyi, M.; Miller, V. A.
    Journal of Clinical Oncology (2006)

    Fulltext@MSK | Save